<DOC>
	<DOC>NCT02565134</DOC>
	<brief_summary>The study is a Phase II, multi center, randomized, double-blind, placebo-controlled study in male and female subjects, aged â‰¥ 19 years with skin pruritus. All subjects will receive BID topical applications of PAC-14028 cream or vehicle for up to 4 weeks.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Skin Pruritus</brief_title>
	<detailed_description />
	<mesh_term>Pruritus</mesh_term>
	<criteria>Male and female patients aged 19 70 years Patients who have eczema or xerosis cutis at the area where investigational product is applied (arm or leg) Patients whose result of the pruritus test (Visual Analogue Scale, VAS) at Visit 1 and 2 is 5 or more Patients whose overall dry skin score of the area where investigational product is applied at Visit 1 and 2 is 2 points or more Patients with pruritus caused by other medical, psychotic and nervous causes other than the skin disease Patients with such skin diseases as malignant tumor or chronic urticaria among patients with skin diseases Patients with simple pruritus caused by such allergic material as scabies, and insect bite wound Patients with the symptom of systemic infection at the time of the participation in the clinical study Patients with a history of taking topical treatment drug, topical steroid agent or antibiotics for the treatment of pruritus within 2 weeks Patients with a history of taking oral steroid agent within 4 weeks Patients with a history of taking a physical treatment for the treatment of pruritus including phototherapy within 4 weeks Pregnant or breastfeeding women Women at a childbearing age who has childbearing potential or has a plan to get pregnant during the clinical study period</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>